<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36851487</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Pediatric Systemic Lupus Erythematous in COVID-19 Era.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">272</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15020272</ELocationID><Abstract><AbstractText>Pediatric systemic lupus erythematosus is a chronic autoimmune disorder with a highly variable course and prognosis. It results in functional abnormalities in the immune system due to intrinsic factors and the use of immunosuppressive therapies associated with underlying comorbidities seem to increase the risk of severe COVID-19 and poor outcomes of the disease in pediatric systemic lupus erythematosus (SLE) patients. The aim of this review is to obtain a better understanding of the existing link between this new viral infection and pediatric lupus. We have analyzed the characteristics of newly diagnosed cases of pediatric SLE following COVID-19 which have been reported in the literature and which describe the impact that COVID-19 has on patients already suffering with pediatric SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lupu</LastName><ForeName>Ancuta</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8147-3632</Identifier><AffiliationInfo><Affiliation>Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miron</LastName><ForeName>Ingrith Crenguta</ForeName><Initials>IC</Initials><Identifier Source="ORCID">0000-0002-9825-6711</Identifier><AffiliationInfo><Affiliation>Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavrilovici</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raileanu</LastName><ForeName>Anca Adam</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starcea</LastName><ForeName>Iuliana Magdalena</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0000-0002-3937-7425</Identifier><AffiliationInfo><Affiliation>Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ioniuc</LastName><ForeName>Ileana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azoicai</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mocanu</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butnariu</LastName><ForeName>Lacramioara Ionela</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Mother and Child Medicine Department, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragan</LastName><ForeName>Felicia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lupu</LastName><ForeName>Vasile Valeriu</ForeName><Initials>VV</Initials><Identifier Source="ORCID">0000-0003-2640-8795</Identifier><AffiliationInfo><Affiliation>Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">child</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>1</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36851487</ArticleId><ArticleId IdType="pmc">PMC9966057</ArticleId><ArticleId IdType="doi">10.3390/v15020272</ArticleId><ArticleId IdType="pii">v15020272</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., Ramsey-Goldman R., Smolen J.S., Wofsy D., Boumpas D.T., Kamen D.L., et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:1400&#x2013;1412. doi: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Asseri A.A., Al-Murayeh R., Abudiah A.M., Elgebally E.I., Aljaser A.M. A case report of pediatric systemic lupus erythematosus with diffuse alveolar hemorrhage following COVID-19 infection: Causation, association, or chance? Medicine. 2022;101:e30071. doi: 10.1097/MD.0000000000030071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000030071</ArticleId><ArticleId IdType="pmc">PMC9387659</ArticleId><ArticleId IdType="pubmed">35984167</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot N., Shaikhani D., Teng Y.K.O., De Leeuw K., Bijl M., Dolhain R.J.E.M., Zirkzee E., Fritsch-Stork R., Bultink I.E.M., Kamphuis S. Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:290&#x2013;301. doi: 10.1002/art.40697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40697</ArticleId><ArticleId IdType="pmc">PMC6590133</ArticleId><ArticleId IdType="pubmed">30152151</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan E.M., Cohen A.S., Fries J.F., Masi A.T., Mcshane D.J., Rothfield N.F., Schaller J.G., Talal N., Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271&#x2013;1277. doi: 10.1002/art.1780251101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780251101</ArticleId><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Vara E., Gilbert M., Ruth N.M. Health disparities in outcomes of pediatric systemic lupus erythematosus. Front Pediatr. 2022;10:879208. doi: 10.3389/fped.2022.879208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.879208</ArticleId><ArticleId IdType="pmc">PMC9614219</ArticleId><ArticleId IdType="pubmed">36313870</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli L., Motta F., De Santis M., Ansari A.A., Gershwin M.E., Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19&#x2014;A systematic review of the literature. J. Autoimmun. 2021;117:102592. doi: 10.1016/j.jaut.2020.102592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102592</ArticleId><ArticleId IdType="pmc">PMC7833462</ArticleId><ArticleId IdType="pubmed">33401171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi M.C., Tamiazzo S., Stobbione P., Agatea L., De Gaspari P., Stecca A., Lauritano E.C., Roveta A., Tozzoli R., Guaschino R. SARS-CoV-2 infection as a trigger of autoimmune response. Clin. Transl. Sci. 2021;14:898&#x2013;907. doi: 10.1111/cts.12953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12953</ArticleId><ArticleId IdType="pmc">PMC8212749</ArticleId><ArticleId IdType="pubmed">33306235</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulou G.B., Maltezou H.C. COVID-19 in Children: Where do we Stand? Arch. Med. Res. 2022;53:1&#x2013;8. doi: 10.1016/j.arcmed.2021.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2021.07.002</ArticleId><ArticleId IdType="pmc">PMC8257427</ArticleId><ArticleId IdType="pubmed">34311990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaiyakulsil C., Sritipsukho P., Satdhabudha A., Bunjoungmanee P., Tangsathapornpong A., Sinlapamongkolkul P., Sritipsukho N. An epidemiological study of pediatric COVID-19 in the era of the variant of concern. PLoS ONE. 2022;17:e0267035. doi: 10.1371/journal.pone.0267035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0267035</ArticleId><ArticleId IdType="pmc">PMC9012366</ArticleId><ArticleId IdType="pubmed">35427379</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Dashboard COVID-19 Cases and Deaths.  [(accessed on 25 November 2022)].  Available online:  https://app.powerbi.com/view?r=eyJrIjoiYWRiZWVkNWUtNmM0Ni00MDAwLTljYWMtN2EwNTM3YjQzYmRmIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9.</Citation></Reference><Reference><Citation>Dong Y., Mo X., Hu Y., Qi X., Jiang F., Jiang Z., Tong S. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145:e20200702. doi: 10.1542/peds.2020-0702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-0702</ArticleId><ArticleId IdType="pubmed">32179660</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (2021) Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID 19)  [(accessed on 25 November 2022)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.</Citation></Reference><Reference><Citation>Tay M.Z., Poh C.M., R&#xe9;nia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 2020;20:363&#x2013;374. doi: 10.1038/s41577-020-0311-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0311-8</ArticleId><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil M.F., Alarc&#xf3;n G.S., Izadi Z., Duarte-Garc&#xed;a A., Re&#xe1;tegui-Sokolova C., Clarke A.E., Wise L., Pons-Estel G.J., Santos M.J., Bernatsky S., et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: Data from the COVID-19 Global Rheumatology Alliance. Ann. Rheum. Dis. 2022;81:970&#x2013;978. doi: 10.1136/annrheumdis-2021-221636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221636</ArticleId><ArticleId IdType="pmc">PMC8882632</ArticleId><ArticleId IdType="pubmed">35172961</ArticleId></ArticleIdList></Reference><Reference><Citation>Udaondo C., Mill&#xe1;n-Longo C., Permuy C., Valladares L., Falces-Romero I., Mu&#xf1;oz-G&#xf3;mez C., Morales-Higuera M., Alcobendas R., Remesal A., Murias S., et al. Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases-cross-sectional study from a reference centre in Spain. Clin. Rheumatol. 2022;41:1779&#x2013;1784. doi: 10.1007/s10067-022-06186-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06186-z</ArticleId><ArticleId IdType="pmc">PMC9055001</ArticleId><ArticleId IdType="pubmed">35489011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Gasparyan A.Y., Zimba O., Kitas G.D. Systemic lupus erythematosus in the light of the COVID-19 pandemic: Infection, vaccination, and impact on disease management. Clin. Rheumatol. 2022;41:2893&#x2013;2910. doi: 10.1007/s10067-022-06227-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06227-7</ArticleId><ArticleId IdType="pmc">PMC9152659</ArticleId><ArticleId IdType="pubmed">35639259</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M., Hyrich K.L., Al-Adely S., Carmona L., Danila M.I., Gossec L., Izadi Z., Jacobsohn L., Katz P., Lawson-Tovey S., et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2020;79:859&#x2013;866. doi: 10.1136/annrheumdis-2020-217871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearsley-Fleet L., Chang M.L., Lawson-Tovey S., Costello R., Fingerhutov&#xe1; &#x160;., &#x160;vestkov&#xe1; N., Belot A., Aeschlimann F.A., Melki I., Kon&#xe9;-Paut I., et al. Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. Ann. Rheum. Dis. 2021;80:872&#x2013;873. doi: 10.1136/annrheumdis-2021-eular.1243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-eular.1243</ArticleId><ArticleId IdType="pmc">PMC8977459</ArticleId><ArticleId IdType="pubmed">35338032</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintero E.T., Pongut&#xe1; A.C.M., da Silva E.A.B., Olivella J., Silvera A.A., Arag&#xf3;n C., V&#xe1;squez L., Collazos E., Vigles K.O., Mart&#xed;nez K., et al. SARS-CoV-2 y s&#x131;ndrome postcovid-19 en reumatolog&#x131;a pediatrica: Una revision exploratoria. Rev. Colomb. Reumatol. 2022 doi: 10.1016/j.rcreu.2022.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rcreu.2022.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslak F., Ozbey D., Yildiz M., Adrovic A., Sahin S., Koker O., Aliyeva A., Guliyeva V., Yalcin G., Inanli G., et al. Asymptomatic SARS-CoV-2 seropositivity: Patients with childhood-onset rheumatic diseases versus healthy children. Clin. Rheumatol. 2022;41:1523&#x2013;1533. doi: 10.1007/s10067-022-06067-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06067-5</ArticleId><ArticleId IdType="pmc">PMC8766358</ArticleId><ArticleId IdType="pubmed">35044502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y.Q., Li H.J., Chen L., Lin S.P. Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases. Sci. Rep. 2022;12:17955. doi: 10.1038/s41598-022-22839-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-22839-0</ArticleId><ArticleId IdType="pmc">PMC9606114</ArticleId><ArticleId IdType="pubmed">36289319</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendebien Z., von Frenckell C., Ribbens C., Andr&#xe9; B., Thys M., Gangolf M., Seidel L., Malaise M.G., Malaise O. Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: Correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments. Ann. Rheum. Dis. 2021;80:e94. doi: 10.1136/annrheumdis-2020-218244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218244</ArticleId><ArticleId IdType="pubmed">32586921</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis J.R., Johnson S.R., Anthony D.D., Arasaratnam R.J., Baden L.R., Bass A.R., Calabrese C., Gravallese E.M., Harpaz R., Kroger A., et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: Version 4. Arthritis Rheumatol. 2022;74:e21&#x2013;e36. doi: 10.1002/art.42109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42109</ArticleId><ArticleId IdType="pmc">PMC9082483</ArticleId><ArticleId IdType="pubmed">35474640</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachiller-Corral J., Boteanu A., Garcia-Villanueva M.J., de la Puente C., Revenga M., Diaz-Miguel M.C., Rodriguez-Garcia A., Morell-Hita J.L., Valero M., Larena C., et al. Risk of severe COVID-19 infection in patients with inflammatory rheumatic diseases. J. Rheumatol. 2021;48:1098&#x2013;1102. doi: 10.3899/jrheum.200755.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200755</ArticleId><ArticleId IdType="pubmed">33722949</ArticleId></ArticleIdList></Reference><Reference><Citation>Filocamo G., Minoia F., Carbogno S., Costi S., Romano M., Cimaz R. Pediatric Rheumatology Group of the Milan Area. Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs. J. Rheumatol. 2021;48:1343&#x2013;1344. doi: 10.3899/jrheum.200483.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200483</ArticleId><ArticleId IdType="pubmed">32335512</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques C.D.L., Kakehasi A.M., Pinheiro M.M., Mota L.M.H., Albuquerque C.P., Silva C.R., Santos G.P.J., Reis-Neto E.T., Matos P., Devide G., et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: First results of ReumaCoV Brasil registry. RMD Open. 2021;7:e001461. doi: 10.1136/rmdopen-2020-001461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001461</ArticleId><ArticleId IdType="pmc">PMC7844930</ArticleId><ArticleId IdType="pubmed">33510041</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel-Quiroz V.R., Ugarte-Gil M.F., Harvey G., Wojdyla D., Pons-Estel G., Quintana R., Esposto A., Garc&#xed;a M.A., Catoggio L.J., Cardiel M.H., et al. Factors predictive of serious infections over time in systemic lupus erythematosus patients: Data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus. 2019;28:1101&#x2013;1110. doi: 10.1177/0961203319860579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319860579</ArticleId><ArticleId IdType="pubmed">31291843</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta M., Balachandran H., Louie R.H.Y., Li H., Agapiou D., Keoshkerian E., Christ D., Rawlinson W., Mina M.M., Post J.J., et al. High activation levels maintained in receptor-binding domain-specific memory B cells in people with severe coronavirus disease 2019. Immunol. Cell Biol. 2022 doi: 10.1111/imcb.12607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12607</ArticleId><ArticleId IdType="pmc">PMC9878167</ArticleId><ArticleId IdType="pubmed">36353774</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordtz R., Kristensen S., Dalgaard L.P.H., Westermann R., Duch K., Lindhardsen J., Torp-Pedersen C., Dreyer L. Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark. J. Clin. Med. 2021;10:3842. doi: 10.3390/jcm10173842.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10173842</ArticleId><ArticleId IdType="pmc">PMC8432052</ArticleId><ArticleId IdType="pubmed">34501290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P., Lagier J.C., Parola P., Meddeb L., Mailhe M., Doudier B., Courjon J., Giordanengo V., Vieira V.E., Dupont H.T., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. 2020;57:106243. doi: 10.1016/j.ijantimicag.2020.106243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106243</ArticleId><ArticleId IdType="pmc">PMC7102549</ArticleId><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim A.H., Sparks J.A., Liew J.W., Putman M.S., Berenbaum F., Duarte-Garc&#xed;a A., Graef E.R., Korsten P., Sattui S.E., Sirotich E., et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann. Intern. Med. 2020;172:819&#x2013;821. doi: 10.7326/M20-1223.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-1223</ArticleId><ArticleId IdType="pmc">PMC7138335</ArticleId><ArticleId IdType="pubmed">32227189</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A., Oliveira E.S.A., Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J. Med. Virol. 2021;93:755&#x2013;759. doi: 10.1002/jmv.26286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26286</ArticleId><ArticleId IdType="pmc">PMC7361589</ArticleId><ArticleId IdType="pubmed">32644224</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifuentes F.T., Callejo &#xc1;.L., Pel&#xe1;ez M.J.T., Pulido O.R., Arag&#xf3;n M.R.M., Urrusuno R.F., Carreras M.I.M., Esteban M.I.M., S&#xe1;nchez V.M., Bonilla A.G., et al. Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine. Med. Clin. 2021;156:166&#x2013;171. doi: 10.1016/j.medcle.2020.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcle.2020.10.012</ArticleId><ArticleId IdType="pmc">PMC7833866</ArticleId><ArticleId IdType="pubmed">33308853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentsch C.T., DeVito N.J., MacKenna B., Morton C.E., Bhaskaran K., Brown J.P., Schultze A., Hulme W.J., Croker R., Walker A.J., et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: A population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021;3:e19&#x2013;e27. doi: 10.1016/S2665-9913(20)30378-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30378-7</ArticleId><ArticleId IdType="pmc">PMC7745258</ArticleId><ArticleId IdType="pubmed">33349815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia-Ramos A.E., Martin-Nares E., Hern&#xe1;ndez-Molina G. New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells. 2021;10:3592. doi: 10.3390/cells10123592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123592</ArticleId><ArticleId IdType="pmc">PMC8700122</ArticleId><ArticleId IdType="pubmed">34944099</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M.C., Ramonell R.P., Nguyen D.C., Cashman K.S., Saini A.S., Haddad N.S., Ley A.M., Kyu S., Howell J.C., Ozturk T., et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat. Immunol. 2020;21:1506&#x2013;1516. doi: 10.1038/s41590-020-00814-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00814-z</ArticleId><ArticleId IdType="pmc">PMC7739702</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Guan F., Candotti F., Benlagha K., Camara N.O.S., Herrada A.A., James L.K., Lei J., Miller H., Kubo M., et al. The role of B cells in COVID-19 infection and vaccination. Front. Immunol. 2022;13:988536. doi: 10.3389/fimmu.2022.988536.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.988536</ArticleId><ArticleId IdType="pmc">PMC9468879</ArticleId><ArticleId IdType="pubmed">36110861</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Upsala J. Med. Sci. 2011;116:227&#x2013;237. doi: 10.3109/03009734.2011.624649.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009734.2011.624649</ArticleId><ArticleId IdType="pmc">PMC3207297</ArticleId><ArticleId IdType="pubmed">22066971</ArticleId></ArticleIdList></Reference><Reference><Citation>Vista E.S., Weisman M.H., Ishimori M.L., Chen H., Bourn R.L., Bruner B.F., Hamijoyo L., Tanangunan R.D., Gal N.J., Robertson J.M., et al. Strong viral associations with SLE among Filipinos. Lupus Sci. Med. 2017;4:e000214. doi: 10.1136/lupus-2017-000214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000214</ArticleId><ArticleId IdType="pmc">PMC5704743</ArticleId><ArticleId IdType="pubmed">29214036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahroum N., Hejly A., Tiosano S., Gendelman O., Comaneshter D., Cohen A.D., Amital H. Chronic hepatitis C viral infection among SLE patients: The significance of coexistence. Immunol. Res. 2017;65:477&#x2013;481. doi: 10.1007/s12026-016-8886-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-016-8886-7</ArticleId><ArticleId IdType="pubmed">28111706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettiol C.O., Ntagerwa J., De Greef A., Tuerlinckx D., Boutsen Y. Possible Case of Children Onset Systemic Lupus Erythematosus Triggered by Covid-19. Res Sq. 2020:1&#x2013;9. doi: 10.21203/rs.3.rs-133376/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-133376/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Maram K.P., Paturi V.R.R., Alla L.S., Bhagavatula M.K. COVID-19 triggered systemic lupus erythematosus in a child: A case report. Int. J. Contemp. Pediatr. 2021;8:1304&#x2013;1306. doi: 10.18203/2349-3291.ijcp20212494.</Citation><ArticleIdList><ArticleId IdType="doi">10.18203/2349-3291.ijcp20212494</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauf A., Thekkudan S.F., Mampilly N., Vijayan A. Childhood-onset systemic lupus erythematosus, probably triggered by severe acute respiratory syndrome coronavirus 2 infection, presenting with autoimmune haemolytic anaemia. Curr. Med. Res. Pract. 2022;12:235. doi: 10.4103/cmrp.cmrp_123_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/cmrp.cmrp_123_21</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran L., Dontaraju V.S., Troyer J., Sahota J. New onset systemic lupus erythematosus after COVID-19 infection: A case report. AME Case Rep. 2022;6:14. doi: 10.21037/acr-21-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acr-21-55</ArticleId><ArticleId IdType="pmc">PMC9010314</ArticleId><ArticleId IdType="pubmed">35475008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani B., Taba S.-M.M., Shayestehpour M. Systemic lupus erythematosus manifestation following COVID-19: A case report. J. Med. Case Rep. 2021;15:29. doi: 10.1186/s13256-020-02582-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-020-02582-8</ArticleId><ArticleId IdType="pmc">PMC7832415</ArticleId><ArticleId IdType="pubmed">33494816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonometti R., Sacchi M.C., Stobbione P., Lauritano E.C., Tamiazzo S., Marchegiani A., Novara E., Molinaro E., Benedetti I., Massone L., et al. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur. Rev. Med. Pharmacol. Sci. 2020;24:9695&#x2013;9697.</Citation><ArticleIdList><ArticleId IdType="pubmed">33015814</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  COVID-19 Vaccine Recommendations for Children and Teens.  [(accessed on 25 November 2022)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccines-children-teens.html.</Citation></Reference><Reference><Citation>COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised.  [(accessed on 25 November 2022)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.</Citation></Reference><Reference><Citation>World Health Organization (WHO) (2022) Coronavirus (COVID-19) Vaccine for Children Aged 5 to 15.  [(accessed on 25 November 2022)].  Available online:  https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-covid-19-vaccination-for-children/coronavirus-covid-19-vaccine-for-children-aged-5-to-15/</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE)  COVID-19 Vaccines.  [(accessed on 25 November 2022)].  Available online:  https://www.nice.org.uk/guidance/conditions-and-diseases/respiratory-conditions/covid19.</Citation></Reference><Reference><Citation>Paediatric Rheumatology European Association  Guidelines and Recommendations. PRES Update Regarding COVID-19 Vaccination in Children with Rheumatic Diseases.  [(accessed on 25 November 2022)].  Available online:  https://www.pres.eu/clinical-affairs/guidelines.html.</Citation></Reference><Reference><Citation>Mason A., Anver H., Lwin M., Holroyd C., Faust S.N., Edwards C.J. Lupus, vaccinations and COVID-19: What we know now. Lupus. 2021;30:1541&#x2013;1552. doi: 10.1177/09612033211024355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211024355</ArticleId><ArticleId IdType="pubmed">34134555</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Cirera S., Calvet J., Berenguer-Llergo A., Pradenas E., Vilaltella M.L., Galisteo C., Blanco J., Masmitj&#xe0; J.G. Glucocorticoids&#x2019; treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients. Sci. Rep. 2022;12:14772. doi: 10.1038/s41598-022-18996-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-18996-x</ArticleId><ArticleId IdType="pmc">PMC9427088</ArticleId><ArticleId IdType="pubmed">36042275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C., Shao W., Chen X., Zhang B., Wang G., Zhang W. Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis. Int. J. Infect. Dis. 2022;114:252&#x2013;260. doi: 10.1016/j.ijid.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8595975</ArticleId><ArticleId IdType="pubmed">34800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Embi P.J., Levy M.E., Naleway A.L., Patel P., Gaglani M., Natarajan K., Dascomb K., Ong T.C., Klein N.P., Liao I.C., et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults&#x2014;Nine States, January-September 2021. Morb. Mortal. Wkly. Rep. 2021;70:1553&#x2013;1559. doi: 10.15585/mmwr.mm7044e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7044e3</ArticleId><ArticleId IdType="pmc">PMC8568092</ArticleId><ArticleId IdType="pubmed">34735426</ArticleId></ArticleIdList></Reference><Reference><Citation>Luxi N., Giovanazzi A., Capuano A., Crisafulli S., Cutroneo P.M., Fantini M.P., Ferrajolo C., Moretti U., Poluzzi E., Raschi E., et al. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Saf. 2021;44:1247&#x2013;1269. doi: 10.1007/s40264-021-01131-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-021-01131-6</ArticleId><ArticleId IdType="pmc">PMC8569292</ArticleId><ArticleId IdType="pubmed">34739716</ArticleId></ArticleIdList></Reference><Reference><Citation>Deepak P., Kim W., Paley M.A., Yang M., Carvidi A.B., Demissie E.G., El-Qunni A.A., Haile A., Huang K., Kinnett B., et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study. Ann. Intern. Med. 2021;174:1572&#x2013;1585. doi: 10.7326/M21-1757.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1757</ArticleId><ArticleId IdType="pmc">PMC8407518</ArticleId><ArticleId IdType="pubmed">34461029</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra MS A.R., Kobayashi T., Suzuki H., Alsuhaibani M., Tofaneto B.M., Bariani L.M., Auler M.d.A., Salinas J.L., Edmond M.B., Doll M., et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis. J. Infect. 2022;84:297&#x2013;310. doi: 10.1016/j.jinf.2021.12.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.12.035</ArticleId><ArticleId IdType="pmc">PMC8720049</ArticleId><ArticleId IdType="pubmed">34982962</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgans H.A., Bradley T., Flebbe-Rehwaldt L., Selvarangan R., Bagherian A., Barnes A.P., Bass J., Cooper A.M., Fischer R., Kleiboeker S., et al. Humoral and cellular response to the COVID-19 vaccine in immunocompromised children. Pediatr. Res. 2022:1&#x2013;6. doi: 10.1038/s41390-022-02374-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-022-02374-4</ArticleId><ArticleId IdType="pmc">PMC9662120</ArticleId><ArticleId IdType="pubmed">36376507</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly P.M., Kim M.Y., Samanovic M., Fernandez-Ruiz R., Ohana S., Deonaraine K.K., Engel A.J., Masson M., Xie X., Cornelius A.R., et al. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. Arthritis Rheumatol. 2022;74:284&#x2013;294. doi: 10.1002/art.41937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41937</ArticleId><ArticleId IdType="pmc">PMC8426963</ArticleId><ArticleId IdType="pubmed">34347939</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R., Kawka L., Dubois M., Ugarte-Gil M.F., Fuentes-Silva Y., Piga M., Arnaud L. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: The international VACOLUP study. Lancet Rheumatol. 2021;3:e613&#x2013;e615. doi: 10.1016/S2665-9913(21)00221-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00221-6</ArticleId><ArticleId IdType="pmc">PMC8294805</ArticleId><ArticleId IdType="pubmed">34312612</ArticleId></ArticleIdList></Reference><Reference><Citation>Rider L.G., Parks C.G., Wilkerson J., Schiffenbauer A.I., Kwok R.K., Noroozi Farhadi P., Nazir S., Ritter R., Sirotich E., Kennedy K., et al. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: Results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology. 2022;61:SI143&#x2013;SI150. doi: 10.1093/rheumatology/keac249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac249</ArticleId><ArticleId IdType="pmc">PMC9248066</ArticleId><ArticleId IdType="pubmed">35460240</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok C.C., Chan K.L., Tse S.M. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus. Vaccine. 2022;40:5959&#x2013;5964. doi: 10.1016/j.vaccine.2022.08.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.08.068</ArticleId><ArticleId IdType="pmc">PMC9444500</ArticleId><ArticleId IdType="pubmed">36085256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavala-Flores E., Salcedo-Matienzo J., Quiroz-Alva A., Berrocal-Kasay A. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin. Rheumatol. 2022;41:1349&#x2013;1357. doi: 10.1007/s10067-021-05980-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05980-5</ArticleId><ArticleId IdType="pmc">PMC8592807</ArticleId><ArticleId IdType="pubmed">34782941</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F., Zhao L., Wang H., Zhang D., Chen J., Wang X., Li T., Ye S. Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity. Lupus Sci. Med. 2022;9:e000657. doi: 10.1136/lupus-2022-000657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000657</ArticleId><ArticleId IdType="pmc">PMC9125751</ArticleId><ArticleId IdType="pubmed">35606018</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbhaiya M., Levine J.M., Siegel C.H., Bykerk V.P., Jannat-Khah D., Mandl L.A. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin. Rheumatol. 2022;41:1619&#x2013;1622. doi: 10.1007/s10067-021-05963-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05963-6</ArticleId><ArticleId IdType="pmc">PMC8556788</ArticleId><ArticleId IdType="pubmed">34716843</ArticleId></ArticleIdList></Reference><Reference><Citation>Heshin-Bekenstein M., Ziv A., Toplak N., Hagin D., Kadishevich D., Butbul Y.A., Saiag E., Kaufman A., Shefer G., Sharon O., et al. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatology. 2022;61:4263&#x2013;4272. doi: 10.1093/rheumatology/keac103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac103</ArticleId><ArticleId IdType="pmc">PMC9383463</ArticleId><ArticleId IdType="pubmed">35179569</ArticleId></ArticleIdList></Reference><Reference><Citation>Akg&#xfc;n &#xd6;., &#xc7;akmak F., Guliyeva V., Demirkan F.G., Tanatar A., Torun S.H., &#xc7;in D., Me&#x15f;e S., A&#x11f;a&#xe7;fidan A., Ayaz N.A. Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. Rheumatology. 2022;61:4482&#x2013;4490. doi: 10.1093/rheumatology/keac140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac140</ArticleId><ArticleId IdType="pmc">PMC9383626</ArticleId><ArticleId IdType="pubmed">35353139</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagy I., Zeller L., Raviv Y., Porges T., Bieber A., Abu-Shakra M. New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: A case series and literature review. Rheumatol. Int. 2022;42:2261&#x2013;2266. doi: 10.1007/s00296-022-05203-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05203-3</ArticleId><ArticleId IdType="pmc">PMC9468534</ArticleId><ArticleId IdType="pubmed">36098769</ArticleId></ArticleIdList></Reference><Reference><Citation>Hejazian S.S., Farnood F., Azar S.A. Dysregulation of immunity in COVID-19 and SLE. Inflammopharmacology. 2022;30:1517&#x2013;1531. doi: 10.1007/s10787-022-01047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-01047-2</ArticleId><ArticleId IdType="pmc">PMC9417079</ArticleId><ArticleId IdType="pubmed">36028612</ArticleId></ArticleIdList></Reference><Reference><Citation>Agmon-Levin N., Zafrir Y., Paz Z., Shilton T., Zandman-Goddard G., Shoenfeld Y. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus. 2009;18:1192&#x2013;1197. doi: 10.1177/0961203309345732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309345732</ArticleId><ArticleId IdType="pubmed">19880567</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M., Agmon-Levin N., Soriano A., Manna R., Maoz-Segal R., Kivity S., Doria A., Shoenfeld Y. Human papillomavirus vaccine and systemic lupus erythematosus. Clin. Rheumatol. 2013;32:1301&#x2013;1307. doi: 10.1007/s10067-013-2266-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-013-2266-7</ArticleId><ArticleId IdType="pubmed">23624585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>